SCHEMBL13825965

SCHEMBL13825965

COC(=O)C1CCC(N)CC1(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MMP2 P08253 1/20 0.35
ANPEP P15144 1/20 0.35
PPM1B O75688 1/20 0.34
PTPN1 P18031 1/20 0.34
PPP1CC P36873 1/20 0.34
CYP1A2 P05177 2/20 0.34
TSHR P16473 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HIF1A Q16665 1/20 0.32
MEN1 O00255 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818751 1.00 ATM (0.36) ATML3MBTL1MMP2ANPEPPPM1B
SCHEMBL20825935 1.00 ATM (0.36) ATML3MBTL1MMP2ANPEPPPM1B
SCHEMBL22189923 1.00 ATM (0.36) ATML3MBTL1MMP2ANPEPPPM1B
SCHEMBL20103729 0.80 SMYD3 (0.40) PPM1BPTPN1PPP1CCCYP2C9CYP2C19
SCHEMBL20103730 0.80 SMYD3 (0.40) PPM1BPTPN1PPP1CCCYP2C9CYP2C19
SCHEMBL20818852 0.80 SLC1A2 (0.39) CYP1A2TSHRCYP2C9CYP2C19MEN1
SCHEMBL20818779 0.80 SLC1A2 (0.39) CYP1A2TSHRCYP2C9CYP2C19MEN1
SCHEMBL20818782 0.80 SLC1A2 (0.39) CYP1A2TSHRCYP2C9CYP2C19MEN1
SCHEMBL31586618 0.78 ATM (0.36) ATML3MBTL1PPM1BPTPN1CYP1A2
SCHEMBL17040334 0.78 ATM (0.37) ATML3MBTL1PPM1BPTPN1PPP1CC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. 2022-06-02 US disclosed
US-11292791-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2022-04-05 US disclosed
EP-3681885-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS Forma Therapeutics, Inc. (US) 2020-07-22 EP disclosed
US-20200216445-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. 2020-07-09 US disclosed
WO-2019055877-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-21 WO disclosed
US-9145391-B2 Bipyridylaminopyridines as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2015-09-29 US disclosed
US-9145391-B2 Bipyridylaminopyridines as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2015-09-29 US disclosed
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2014-09-04 US disclosed
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2014-09-04 US disclosed
WO-2012154518-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS SYK, BTK, LCK ATM 561/4885L3MBTL1 3948/4885MMP2 2444/4885
US-20200216445-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ATM 1060/4885L3MBTL1 669/4885MMP2 2811/4885
US-11292791-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 ATM 1060/4885L3MBTL1 669/4885MMP2 2811/4885
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ATM 1060/4885L3MBTL1 669/4885MMP2 2811/4885
US-20220169647-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ATM 1060/4885L3MBTL1 669/4885MMP2 2811/4885
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 ATM 1060/4885L3MBTL1 669/4885MMP2 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.